CANNAPHARMARX, INC.
CANNAPHARMARX, INC.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-03-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||
Cash | - | - | - | - | - | - | - | - | - | 0 | |||||
Series B Preferred Stock | - | - | - | - | 0 | 0 | 0 | - | 0 | - | |||||
Series A Preferred Stock | - | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | |||||
Series C Preferred Stock | - | 0 | 0 | 0 | -0 | 0 | 0 | - | 0 | - | |||||
Series D Preferred Stock | - | - | - | 0 | - | - | - | - | - | - | |||||
Series B Preferred Stocks | - | 0 | 0 | - | - | - | 0 | - | - | - | |||||
Cash And Cash Equivalents At Carrying Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Other Receivables Net Current | - | - | - | - | - | - | - | - | - | 0 | |||||
Prepaid Expense Current | - | - | - | - | - | - | - | - | - | 0 | |||||
Other Assets Current | - | - | - | - | - | - | - | - | - | 0 | |||||
Accounts Receivable Net Current | 0 | 0 | 0 | - | - | - | 0 | - | 0 | - | |||||
Accounts Receivable Net | - | - | 0 | 1 | 0 | 0 | 0 | 0 | - | - | |||||
Inventory Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | |||||
Assets Current | |||||||||||||||
Assets Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | |||||
Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Assets Noncurrent | |||||||||||||||
Finance Lease Right Of Use Asset | - | - | - | - | - | - | - | - | - | 5 | |||||
Operating Lease Right Of Use Asset | 5 | 5 | 6 | 6 | 6 | 5 | 5 | 6 | 6 | - | |||||
Investments | - | - | 0 | 5 | 5 | 5 | 5 | 5 | 5 | 0 | |||||
Assets | 7 | 7 | 7 | 12 | 11 | 11 | 11 | 12 | 11 | 5 | |||||
Liabilities And Stockhold… | |||||||||||||||
Accounts Payable Current | - | - | - | - | - | - | - | - | 8 | 8 | |||||
Bank Overdrafts | - | - | - | - | - | - | - | - | - | 0 | |||||
Accounts Payable And Accrued Liabilities Current | 6 | 10 | 10 | 10 | 10 | 13 | 9 | - | - | - | |||||
Notes Payable | - | - | - | 0 | 0 | 0 | 7 | 7 | - | - | |||||
Interest Payable Current | 2 | 2 | 2 | - | - | - | 2 | - | 1 | 0 | |||||
Other Accounts Payable And Accrued Liabilities | - | - | 5 | - | - | - | 1 | 9 | - | - | |||||
Deferred Revenue Current | 0 | 0 | 0 | - | - | 0 | 0 | - | - | - | |||||
Litigation Reserve Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | |||||
Liabilities Current | |||||||||||||||
Liabilities Current | 33 | 31 | 32 | 28 | 29 | 27 | 26 | 23 | 29 | 20 | |||||
Deferred Revenue | - | - | - | - | - | - | - | 0 | - | - | |||||
Notes Payable Current | 0 | 0 | 0 | - | - | - | 7 | - | 3 | 8 | |||||
Convertible Notes Payable Current | - | 1 | 1 | - | - | - | 1 | - | - | - | |||||
Convertible Notes Payable | - | - | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | |||||
Derivative Liabilities Current | 3 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 9 | 1 | |||||
Accrued Royalties Current | 0 | 0 | 0 | - | - | - | 0 | - | - | - | |||||
Operating Lease Liability Current | 1 | 1 | 1 | - | - | - | 1 | - | - | - | |||||
Liabilities Noncurrent | |||||||||||||||
Operating Lease Liability Noncurrent | 5 | 5 | 5 | - | - | - | 5 | - | - | - | |||||
Liabilities | 38 | 37 | 37 | 34 | 34 | 32 | 31 | 28 | 35 | 26 | |||||
Preferred Stock Value | - | - | - | - | - | - | - | 0 | - | - | |||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Stockholders Equity | |||||||||||||||
Stockholders Equity | -31 | -30 | -30 | -23 | -23 | -21 | -20 | -17 | -24 | -21 | |||||
Treasury Stock Common Value | - | - | - | - | - | 0 | 0 | 0 | - | - | |||||
Common Stock Shares Subscriptions | - | 0 | 0 | - | - | - | 0 | - | - | - | |||||
Additional Paid In Capital | 83 | 82 | 82 | 81 | 80 | 80 | 80 | 80 | 79 | 75 | |||||
Retained Earnings Accumulated Deficit | -115 | -113 | -112 | -105 | -103 | -102 | -101 | -97 | -103 | -99 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | 1 | 0 | -0 | 0 | -0 | 1 | 1 | 0 | 0 | 0 | |||||
Liabilities And Stockholders Equity | 7 | 7 | 7 | 12 | 11 | 11 | 11 | 12 | 11 | 5 | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Authorized | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | |||||
Common Stock Shares Issued | 709 | 679 | 663 | 663 | 663 | 663 | 663 | 663 | 5 | 295 | |||||
Shares Outstanding | 709 | 679 | 663 | 663 | 663 | 663 | 663 | 663 | 560 | 295 | |||||
Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | - | 0.001 | 0.001 | - | - | |||||
Treasury Stock Common Shares | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | |||||
Preferred Stock Shares Authorized | - | - | 3 | 3 | 3 | 3 | - | - | - | - | |||||
Preferred Stock Shares Outstanding | - | - | 1 | 1 | 1 | - | 1 | - | - | - | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -81.08% | -37.84% | -45.95% | - | - | - | - | - | - | - | - | - |
| 2025 | 41.94% | 25.81% | 3.23% | 0.00% | -6.25% | 56.25% | -11.11% | 95.56% | -11.11% | -6.98% | -13.95% | -46.51% |
| 2024 | -20.00% | -16.00% | -36.00% | - | - | - | -5.88% | -7.06% | -15.29% | -20.00% | -38.18% | -29.09% |
| 2023 | 0.00% | -82.36% | -90.00% | -75.00% | -88.57% | -87.86% | -26.32% | -47.37% | -47.37% | - | - | - |
| 2022 | - | - | - | - | - | - | - | - | - | 0.00% | -42.86% | -86.43% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Metrics | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-03-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Metric history beyond 3 years is for subscribers only. Unlock 17+ years of history across 90+ calculated metrics Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||
| Current Ratio | 0.04 | 0.03 | 0.04 | 0.05 | 0.04 | 0.05 | 0.04 | 0.07 | 0.04 | 0.00 | |||||
| Quick Ratio | 0.00 | 0.00 | 0.01 | 0.02 | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | |||||
| Working Capital | -31.24M | -30.56M | -30.28M | -27.01M | -27.76M | -25.66M | -24.73M | -21.01M | -28.20M | -20.17M | |||||
Leverage & Debt | |||||||||||||||
| Debt to Equity | -1.22 | -1.22 | -1.23 | -1.52 | -1.51 | -1.55 | -1.55 | -1.70 | -1.48 | -1.25 | |||||
| Interest Coverage TTM | -1.91 | -1.84 | -1.71 | -1.69 | -1.47 | -1.50 | -1.64 | -1.72 | -2.05 | -2.47 | |||||
| Debt Ratio | 5.47 | 5.60 | 5.30 | 2.94 | 2.97 | 2.83 | 2.83 | 2.42 | 3.07 | 5.00 | |||||
Efficiency & Turnover | |||||||||||||||
| Asset Turnover TTM | 0.19 | 0.19 | 0.15 | 0.15 | 0.12 | 0.14 | 0.10 | 0.04 | 0.00 | 0.00 | |||||
| Days Sales Outstanding TTM | 1.46 | 1.53 | 22.26 | - | - | - | 0.78 | - | 199.81 | - | |||||
| Receivables Turnover TTM | 249.44 | 238.24 | 16.39 | - | - | - | 469.45 | - | 1.83 | - | |||||
Per Share Metrics | |||||||||||||||
| Diluted EPS TTM | -0.02 | -0.02 | -0.02 | - | -0.00 | -0.02 | -0.02 | -0.02 | -0.04 | -0.03 | |||||
| Free Cash Flow Per Share TTM | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Margin Metrics | |||||||||||||||
| Gross Profit Margin TTM | -88.82% | -120.40% | -153.06% | -217.23% | -266.04% | -297.50% | - | - | - | - | |||||
| Operating Profit Margin TTM | -170.13% | -202.65% | -245.77% | -280.18% | -320.25% | -372.89% | -524.11% | -848.10% | -11,884.78% | - | |||||
| Net Profit Margin TTM | -666.22% | -654.22% | -817.19% | -114.94% | -21.61% | -917.07% | -1,276.64% | -4,133.44% | -60,266.10% | - | |||||
Growth Metrics | |||||||||||||||
| Net Revenue Growth (1Y) | 24.81% | 43.17% | 66.09% | 404.63% | 5,168.10% | - | - | - | - | - | |||||
| Net Income Growth (1Y) | 3,747.09% | 2.14% | 6.32% | -85.97% | -98.11% | 41.36% | 26.99% | 77.49% | 82.54% | -38.69% | |||||
| EPS Growth (1Y) | 3,634.46% | -0.27% | 6.32% | -85.97% | -99.00% | -37.03% | -42.56% | -21.53% | 9.90% | -49.91% | |||||
Valuation Metrics | |||||||||||||||
| P/E TTM | -0.14 | -0.27 | -0.31 | -1.01 | -8.78 | -0.25 | -0.51 | -0.41 | -0.33 | -0.55 | |||||
| P/B TTM | -0.05 | -0.10 | -0.11 | -0.09 | -0.11 | -0.13 | -0.27 | -0.34 | -0.22 | -0.20 | |||||
| P/S TTM | 0.96 | 1.76 | 2.53 | 1.17 | 1.90 | 2.29 | 6.54 | 16.86 | 200.77 | - | |||||
| Market Cap | 1.64M | 2.92M | 3.45M | 1.99M | 2.58M | 2.65M | 5.37M | 5.70M | 5.19M | 4.13M | |||||
| Enterprise Value | 2.06M | 4.41M | 4.94M | 2.47M | 3.05M | 3.11M | 20.02M | 12.54M | 8.51M | 12.00M | |||||
Calculated Values | |||||||||||||||
| Free Cash Flow TTM | -112.28K | -431.38K | -789.10K | -2.03M | -2.75M | -2.85M | -2.20M | -2.50M | -1.60M | -2.14M | |||||
| Net Debt | 422.79K | 1.49M | 1.50M | 477.68K | 466.90K | 459.67K | 14.65M | 6.84M | 3.32M | 7.87M | |||||
Per-Share and Margin | |||||||||||||||
| EPS TTM | |||||||||||||||
| Adjusted EPS TTM | |||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||
| Pretax Margin TTM | |||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||
Turnover Ratios and Averages | |||||||||||||||
| Average Assets | |||||||||||||||
| Average Equity | |||||||||||||||
| Average Inventory | |||||||||||||||
| Average Receivables | |||||||||||||||
| Average Accounts Payables | |||||||||||||||
| Inventory Turnover TTM | |||||||||||||||
| Payables Turnover TTM | |||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||
| Working Capital to Revenue | |||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||
Growth Rates | |||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||
| EPS Growth (3Y) | |||||||||||||||
| EPS Growth (5Y) | |||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||
| Cash Ratio | |||||||||||||||
| Net Working Capital | |||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||
| Net Debt to Equity | |||||||||||||||
| Altman A | |||||||||||||||
| Altman B | |||||||||||||||
| Altman C | |||||||||||||||
| Altman D | |||||||||||||||
| Altman E | |||||||||||||||
| Altman Z-Score | |||||||||||||||
| ROA TTM | |||||||||||||||
| ROE TTM | |||||||||||||||
| NOPAT TTM | |||||||||||||||
| ROIC TTM | |||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||
| Payout Ratio TTM | |||||||||||||||
| Dilution Ratio | |||||||||||||||
| Retained Earnings to Equity | |||||||||||||||
| Treasury Stock to Equity | |||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||
| NCAV | |||||||||||||||
| NCAV Per Share TTM | |||||||||||||||
Valuation Ratios | |||||||||||||||
| P/CF TTM | |||||||||||||||
| Dividend Yield TTM | |||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||
| EV EBITDA TTM | |||||||||||||||
| EV EBIT TTM | |||||||||||||||
| Stock Compensation TTM | |||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||
| Billings TTM | |||||||||||||||
| Total Debt | |||||||||||||||
| Invested Capital | |||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
CANNAPHARMARX, INC. (CPMD) — SEC Financial Statements & Analysis
CANNAPHARMARX, INC. (CPMD) is a pharmaceutical preparations company, incorporated in DE. CANNAPHARMARX, INC. trades on OTC as: CPMD. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), CANNAPHARMARX, INC. reported a 24.81% year-over-year revenue growth, a Gross Profit Margin of -88.82% (TTM), a Debt-to-Equity ratio of -1.22x, a Price-to-Sales (P/S) ratio of 0.96x (TTM), a Price-to-Book (P/B) ratio of -0.05x (TTM), at a market cap of $1.64M. Figures below are sourced from SEC EDGAR, as-filed.
- Net Revenue TTM Growth 1Y
- 24.81%
- Gross Profit Margin TTM
- -88.82%
- Debt To Equity
- -1.22x
- P/S TTM
- 0.96x
- P/B TTM
- -0.05x
- Market Cap
- $1.64M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is CANNAPHARMARX, INC. in?
CANNAPHARMARX, INC. (CPMD) operates in the Pharmaceutical Preparations industry.
What is CPMD's market cap?
CANNAPHARMARX, INC. (CPMD) has a market capitalization of $1.64M as of 2026-06-30.
What exchange does CPMD trade on?
CANNAPHARMARX, INC. (CPMD) trades on the OTC.
Where is CANNAPHARMARX, INC. incorporated?
CANNAPHARMARX, INC. is incorporated in DE.